1887
Rapid communication Open Access
Like 0

Abstract

We describe the development of a risk assessment profile tool that incorporates data from multiple domains to help determine activities and events where rapid antigen detection tests (Ag-RDT) could be used to screen asymptomatic individuals to identify infectious cases as an additional mitigation measure to reduce transmission of SARS-CoV-2. The tool aims to stratify, in real time, the overall risk of SARS-CoV-2 transmission associated with common activities and events, and this can be matched to an appropriate Ag-RDT testing protocol.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.3.2101202
2022-01-20
2022-10-03
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2022.27.3.2101202
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/3/eurosurv-27-3-1.html?itemId=/content/10.2807/1560-7917.ES.2022.27.3.2101202&mimeType=html&fmt=ahah

References

  1. Peeling RW, Olliaro PL, Boeras DI, Fongwen N. Scaling up COVID-19 rapid antigen tests: promises and challenges. Lancet Infect Dis. 2021;21(9):e290-5.  https://doi.org/10.1016/S1473-3099(21)00048-7  PMID: 33636148 
  2. Economic and Social Research Institute (ESRI). 2021. Social activity measure – wave 1. Dublin: ESRI; 2021. Available from: https://www.esri.ie/publications/social-activity-measure-wave-1
  3. Thakur B, Dubey P, Benitez J, Torres JP, Reddy S, Shokar N, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep. 2021;11(1):8562.  https://doi.org/10.1038/s41598-021-88130-w  PMID: 33879826 
  4. European Centre for Disease Prevention and Control (ECDC). Options for the use of rapid antigen detection tests for COVID-19 in the EU/EEA – first update. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/options-use-rapid-antigen-tests-covid-19-eueea-first-update
  5. Beck A, Shaver N, Bennett D, Vyas N, Zitikyte G, Skidmore B, et al. Living rapid review on COVID-19 transmission and different activities or settings. PROSPERO 2021 CRD42021284107. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021284107
  6. Beck A, Bennett A, Shaver N, Vyas N, Zitikyte G, Whelan B, et al. COVID-19 rapid antigen testing and transmission risk associated with different activities or settings: Two living rapid reviews. Open Science Framework (OSF); 18 Jan2022. Available from: https://osf.io/pqjyr
  7. Beck A, Shaver N, Bennett D, Vyas N, Zitikyte G, Skidmore B, et al. Living rapid review on COVID-19 rapid antigen testing strategies. PROSPERO 2021 CRD42021284168. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021284168
  8. Chiu RYT, Kojima N, Mosley GL, Cheng KK, Pereira DY, Brobeck M, et al. Evaluation of the INDICAID COVID-19 rapid antigen test in symptomatic populations and asymptomatic community testing. Microbiol Spectr. 2021;9(1):e0034221.  https://doi.org/10.1128/Spectrum.00342-21  PMID: 34346748 
  9. Lindner AK, Nikolai O, Kausch F, Wintel M, Hommes F, Gertler M, et al. Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab. Eur Respir J. 2021;57(4):2003961.  https://doi.org/10.1183/13993003.03961-2020  PMID: 33303544 
  10. Klein JAF, Krüger LJ, Tobian F, Gaeddert M, Lainati F, Schnitzler P, et al. Head-to-head performance comparison of self-collected nasal versus professional-collected nasopharyngeal swab for a WHO-listed SARS-CoV-2 antigen-detecting rapid diagnostic test. Med Microbiol Immunol. 2021;210(4):181-6.  https://doi.org/10.1007/s00430-021-00710-9  PMID: 34028625 
  11. Nikolai O, Rohardt C, Tobian F, Junge A, Corman VM, Jones TC, et al. Anterior nasal versus nasal mid-turbinate sampling for a SARS-CoV-2 antigen-detecting rapid test: does localisation or professional collection matter? Infect Dis (Lond). 2021;53(12):947-52.  https://doi.org/10.1080/23744235.2021.1969426  PMID: 34445926 
  12. Crozier A, Rajan S, Buchan I, McKee M. Put to the test: use of rapid testing technologies for covid-19. BMJ. 2021;372(208):n208.  https://doi.org/10.1136/bmj.n208  PMID: 33536228 
  13. López Seguí F, Estrada Cuxart O, Mitjà I Villar O, Hernández Guillamet G, Prat Gil N, Maria Bonet J, et al. A cost-benefit analysis of the COVID-19 asymptomatic mass testing strategy in the north Metropolitan area of Barcelona. Int J Environ Res Public Health. 2021;18(13):7028.  https://doi.org/10.3390/ijerph18137028  PMID: 34209328 
  14. Department of the Taoiseach. Statement on COVID-19 public health measures - 16 November 2021. Dublin: Department of the Taoiseach; 2021. Available from: https://www.gov.ie/en/press-release/b4bec-statement-on-covid-19-public-health-measures-16-november-2021
  15. Wachinger J, Olaru ID, Horner S, Schnitzler P, Heeg K, Denkinger CM. The potential of SARS-CoV-2 antigen-detection tests in the screening of asymptomatic persons. Clin Microbiol Infect. 2021;27(11):1700.e1-3.  https://doi.org/10.1016/j.cmi.2021.07.020  PMID: 34325065 
  16. Peeling RW, Heymann DL, Teo YY, Garcia PJ. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2021;S0140-6736(21)02346-1.  https://doi.org/10.1016/S0140-6736(21)02346-1  PMID: 34942102 
  17. Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021;3(4):CD013705.  https://doi.org/10.1002/14651858.CD013705.pub2  PMID: 33760236 
/content/10.2807/1560-7917.ES.2022.27.3.2101202
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error